Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor

[1]  T. Tateno,et al.  L-type amino acid transporter 1, LAT1, in growth hormone-producing pituitary tumor cells , 2020, Molecular and Cellular Endocrinology.

[2]  D. Nonaka,et al.  Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours , 2019, Neuroendocrinology.

[3]  S. Asa,et al.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors , 2019, Endocrine Pathology.

[4]  J. Strosberg,et al.  Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. , 2019, The oncologist.

[5]  W. Fu,et al.  Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms , 2018, Medicine.

[6]  B. Taylor,et al.  Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab , 2018, The Journal of clinical endocrinology and metabolism.

[7]  G. Pereira,et al.  Presenting national HIV/AIDS and sexually transmitted disease research in Brazil , 2018, Medicine.

[8]  Patty W. Wright,et al.  Central nervous system histoplasmosis , 2018, Medicine.

[9]  O. Dekkers,et al.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. , 2018, European journal of endocrinology.

[10]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. , 2018, European journal of endocrinology.

[11]  P. Chanson,et al.  Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. , 2017, European journal of endocrinology.

[12]  N. Lehman,et al.  Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing’s disease , 2017, Diagnostic Pathology.

[13]  P. Chanson,et al.  From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. , 2017, Endocrine-related cancer.

[14]  Shih-Hsiu J Wang,et al.  Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. , 2016, CNS oncology.

[15]  M. Komada,et al.  The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. , 2016, European journal of endocrinology.

[16]  P. Catalano,et al.  A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). , 2015 .

[17]  G. Kaltsas,et al.  Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects , 2015, Neuroendocrinology.

[18]  G. Johannsson,et al.  Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. , 2015, The Journal of clinical endocrinology and metabolism.

[19]  L. Denaro,et al.  Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center , 2015, Journal of Neuro-Oncology.

[20]  M. Daimon,et al.  Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo , 2014, Molecular and Cellular Endocrinology.

[21]  B. Zacharia,et al.  High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. , 2014, Neurosurgery.

[22]  J. Chabot,et al.  Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience , 2013, Cancer Chemotherapy and Pharmacology.

[23]  R. Fine,et al.  Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature , 2012, Oncology.

[24]  S. Knappskog,et al.  Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy , 2011, Cancer.

[25]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[26]  H. Hammes,et al.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[27]  J. Bruce,et al.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor , 2011, Pituitary.

[28]  T. Tateno,et al.  Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. , 2009, Endocrine journal.

[29]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[30]  N. Matsubara,et al.  Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. , 2007, Oncology reports.